Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

Ticiana A Leal; Suresh S Ramalingam

doi:10.1016/j.xcrm.2022.100691

Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

Cell Rep Med. 2022 Jul 19;3(7):100691. doi: 10.1016/j.xcrm.2022.100691.

Authors

Ticiana A Leal¹, Suresh S Ramalingam²

Affiliations

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: ticiana.a.leal@emory.edu.
² Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

Abstract

Forde et al.¹ reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).

Trial registration: ClinicalTrials.gov NCT04025879.

Publication types

Randomized Controlled Trial
Comment

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Neoadjuvant Therapy
Nivolumab / administration & dosage
Progression-Free Survival

Substances

Antineoplastic Agents, Immunological
Nivolumab

Associated data

ClinicalTrials.gov/NCT04025879